Does Dapagliflozin influence arterial stiffness and levels of circulating anti-aging hormone soluble Klotho in people with type 2 diabetes and kidney disease? Results of a randomized parallel group clinical trial.

Janaka Karalliedde

Does Dapagliflozin influence arterial stiffness and levels of circulating anti-aging hormone soluble Klotho in people with type 2 diabetes and kidney disease? Results of a randomized parallel group clinical trial.

SCMMS Southbank

Research output: Contribution to journal › Article › peer-review

Original language	English
Journal	Frontiers in Cardiovascular Medicine
Volume	Front Cardiovasc Med. 2022 Sep 30;9:992327. doi: 10.3389/fcvm.2022.992327. eCollection 2022.
Publication status	Published - 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

Karalliedde, Janaka. / Does Dapagliflozin influence arterial stiffness and levels of circulating anti-aging hormone soluble Klotho in people with type 2 diabetes and kidney disease? Results of a randomized parallel group clinical trial. In: Frontiers in Cardiovascular Medicine. 2022 ; Vol. Front Cardiovasc Med. 2022 Sep 30;9:992327. doi: 10.3389/fcvm.2022.992327. eCollection 2022.

@article{8ec3287388d44dc6a32efea41fb6e3c9,

title = "Does Dapagliflozin influence arterial stiffness and levels of circulating anti-aging hormone soluble Klotho in people with type 2 diabetes and kidney disease? Results of a randomized parallel group clinical trial.",

author = "Janaka Karalliedde",

year = "2022",

language = "English",

volume = "Front Cardiovasc Med. 2022 Sep 30;9:992327. doi: 10.3389/fcvm.2022.992327. eCollection 2022.",

journal = "Frontiers in Cardiovascular Medicine",

issn = "2297-055X",

publisher = "Frontiers Media S.A.",

}

Karalliedde, J 2022, 'Does Dapagliflozin influence arterial stiffness and levels of circulating anti-aging hormone soluble Klotho in people with type 2 diabetes and kidney disease? Results of a randomized parallel group clinical trial.', Frontiers in Cardiovascular Medicine, vol. Front Cardiovasc Med. 2022 Sep 30;9:992327. doi: 10.3389/fcvm.2022.992327. eCollection 2022.

Does Dapagliflozin influence arterial stiffness and levels of circulating anti-aging hormone soluble Klotho in people with type 2 diabetes and kidney disease? Results of a randomized parallel group clinical trial. / Karalliedde, Janaka.
In: Frontiers in Cardiovascular Medicine, Vol. Front Cardiovasc Med. 2022 Sep 30;9:992327. doi: 10.3389/fcvm.2022.992327. eCollection 2022., 2022.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Does Dapagliflozin influence arterial stiffness and levels of circulating anti-aging hormone soluble Klotho in people with type 2 diabetes and kidney disease? Results of a randomized parallel group clinical trial.

AU - Karalliedde, Janaka

PY - 2022

Y1 - 2022

M3 - Article

SN - 2297-055X

VL - Front Cardiovasc Med. 2022 Sep 30;9:992327. doi: 10.3389/fcvm.2022.992327. eCollection 2022.

JO - Frontiers in Cardiovascular Medicine

JF - Frontiers in Cardiovascular Medicine

ER -